Quantitative and Systems Pharmacology Workshop II 09/09/2010 to 09/10/2010
NIH - Lister Hill Auditorium
Bethesda, Maryland
United States
Image  
printable format

Speaker References

Sandra RB Allerheiligen
Merck Research Laboratories
 
 J Pharmacokinet Pharmacodyn. 2006 Jun;33 (3):369-93.
 
 Clin Pharmacol Ther. 2010 Jul;88(1):135-7.
 
 Clin Pharmacol Ther. 2010 Aug;88(2):158-61.
 
Fostering Culture and Optimizing Organizational Structure for Implementing Model-Based Drug Development. 
J Clinical Pharmacology (in press 2010)
 
 J Clin Pharmacol. 2008 May;48(5):632-49.
 
Clin Pharmacol Ther. 2007 Aug;82(2):137-42.
 
AAPS J.2008 Dec;10(4):552-9.
 
Russ Altman
Stanford University
 
Clin Pharmacol Ther. 2009 Aug;86(2):183-9.
 
Pac Symp Biocomput. 2010:305-14.
 
Andrea Califano
Columbia University
 
Nature. 2010 Jan 21;463(7279):318-25.
 
Towards patient-based cancer therapeutics, The Cancer Target Discovery and Development Network, Nature Biotechnology, in press
Molecular Systems Biology 6, (8 June 2010)
 
 Nat Biotechnol. 2009 Sep;27(9):829-39.
 
Nature. 2009 Jun 4;459(7247):717-21
 
Mol Syst Biol. 2008;4:169.
 
Jenny Chien
Eli Lilly and Company
 
The Application of Drug-Disease Models in the Development of Anti-hyperglycemic Agents. 
Chapter 9 in “Clinical Trial Simulations:
 Applications and Trends” ed. H Kimko and P Carl, Springer Science
+ Business Media, 2010. (in press)
 
Basic Clin Pharmacol Toxicol. 2010 Mar;10 (3):189-94..
  
 J Clin Pharmacol. 2010 Aug;50(8):861-72..
 
Am J Physiol Endocrinol Metab. 2008 Dec;295 (6):E1462-79.
 
David D’Argenio
University of Southern California
 
 Bioinformatics. 2010 Mar 15;26(6):807-13.
 
a Posteriori Estimation.
 Comput Stat Data Anal. 2009 Oct 1;53(12):3907- 3915.
 
Clin Pharmacokinet. 2008;47(7):417-48.
 
Kathleen M. Giacomini
University of California San Francisco
 
 Nat Rev Drug Discov. 2010 Mar;9(3):215-36.
 
 Protein Sci. 2010 Mar;19(3):412-28.
 
Nathanael Gray
Dana-Farber Cancer Institute/ Harvard University
 
 Nature. 2010 Jan 28;463(7280):501-6.
 
Richard Lalonde
Pfizer Inc
 
J Clin Pharmacol. 2009 Nov;49(11):1297-308.
 
Donald E. Mager
University of Buffalo
 
Clin Pharmacol Ther. 2008 Jun; 83(6):909-12. 
 
 
Timothy J. Mitchison
Harvard Medical School
 
Cancer Cell. 2009 Oct 6;16(4):347-58
 
Brian Shoichet
University of California, San Francisco
 
Nat Biotechnol. 2007 Feb; 25(2):197-206.
 
Nature. 2009 Nov 12; 462(7270):175-81.
 
Peter Sorger
Harvard Medical School
 
Curr Opin Chem Biol. 2009 Dec; 13(5-6):556-61
 
Mol Cell Proteomics. 2010 May 10.
 
Clin Pharmacol Ther. 2010 Jul;88(1):34-8
 
Shankar Subramaniam
University of California San Diego
 
 insulin sensitization.
 Proc Natl Acad Sci U S A. 2009 Nov 3;106  (44):18745-50.
 
 J Clin Invest. 2007 Jun; 117(6):1658-69.
 
Syst Synth Biol. 2008 Dec;2(3-4):95-104.
 
 Bioinformatics. 2004 Nov 22;20(17):3108-27.
 
Piet Van der Graaf
Pfizer Global Research and Development
 
Drug Discov Today. 2007 Dec; 12(23-24):1018-24
 
Antimicrob Agents Chemother. 2010 Mar; 54(3):1179-85.
 
J Theor Biol. 2009 Jan 21;256(2):253-62.
 
 Future Medicinal Chemistry, Nov 2009, Vol. 1, No. 8, Pages 1371-1374.
 
Yaning Wang, Ph.D.
Food and Drug Administration
 
Clin Pharmacol Ther. 2009 Aug;86(2):167-74.
 
Annu Rev Pharmacol Toxicol. 2009;49:291-301.
 
Lani Wu
University of Texas Southwestern Medical Center at Dallas
 
Mol Syst Biol. 2010 May 11;6:369.
 
J Cell Biol. 2009 Nov 2; 187(3):375-84.